ID   HSC-4
AC   CVCL_1289
SY   HSC4
DR   BTO; BTO:0002026
DR   CLO; CLO_0051567
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   BioGRID_ORCS_Cell_line; 892
DR   BioSample; SAMN03471638
DR   BioSample; SAMN03472086
DR   BioSample; SAMN10987856
DR   cancercelllines; CVCL_1289
DR   Cell_Model_Passport; SIDM00588
DR   CGH-DB; 365-2
DR   ChEMBL-Cells; CHEMBL3308109
DR   ChEMBL-Targets; CHEMBL1075469
DR   Cosmic; 907062
DR   Cosmic; 930332
DR   Cosmic; 932149
DR   Cosmic; 1046029
DR   Cosmic; 1118790
DR   Cosmic; 1120699
DR   Cosmic; 1123040
DR   Cosmic; 1140782
DR   Cosmic; 1219866
DR   Cosmic; 2266785
DR   Cosmic; 2546837
DR   Cosmic-CLP; 907062
DR   DepMap; ACH-000546
DR   EGA; EGAS00001000978
DR   GDSC; 907062
DR   GEO; GSM827203
DR   GEO; GSM850384
DR   GEO; GSM887135
DR   GEO; GSM888206
DR   GEO; GSM1669906
DR   GEO; GSM7695972
DR   GEO; GSM7695973
DR   IARC_TP53; 1102
DR   JCRB; JCRB0624
DR   LiGeA; CCLE_513
DR   LINCS_LDP; LCL-1218
DR   PharmacoDB; HSC4_622_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_1289
DR   PubChem_Cell_line; CVCL_1289
DR   RCB; RCB1902
DR   TKG; TKG 0489
DR   Wikidata; Q54896390
RX   PubMed=1570156;
RX   PubMed=2228902;
RX   PubMed=2585303;
RX   PubMed=7591301;
RX   PubMed=9023415;
RX   PubMed=9247707;
RX   PubMed=9290701;
RX   PubMed=10069537;
RX   PubMed=10741724;
RX   PubMed=11416159;
RX   PubMed=11755821;
RX   PubMed=12738951;
RX   PubMed=17052259;
RX   PubMed=17325662;
RX   PubMed=17599052;
RX   PubMed=18097548;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=22460905;
RX   PubMed=26589293;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=30971826;
RX   PubMed=31068700;
RX   PubMed=31978347;
RX   PubMed=32990596;
RX   PubMed=35839778;
RX   PubMed=37949965;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Japanese.
CC   Doubling time: ~25 hours (Note=Lots 04012002 and 06292012), ~21 hours (Note=Lot 03202018) (JCRB=JCRB0624).
CC   HLA typing: A*24:02,31:01; B*07:02,51:01; C*07:02,14:02 (PubMed=9023415).
CC   HLA typing: A*24:02,31:01; B*07:02,51:01; C*07:02,14:02 (PubMed=26589293).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.238C>T) (p.Pro94Leu, c.281C>T); ClinVar=VCV000009409; Zygosity=Homozygous (DepMap).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (PubMed=18097548; DepMap).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31068700).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Unspecified (PubMed=1570156; PubMed=10741724).
CC   Omics: CRISPR phenotypic screen.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0%; Native American=0%; East Asian, North=84.74%; East Asian, South=13.79%; South Asian=1.33%; European, North=0%; European, South=0.12% (PubMed=30894373).
CC   Derived from site: Metastatic; Cervical lymph node; UBERON=UBERON_0002429.
ST   Source(s): Cosmic-CLP; Genomics_Center_BCF_Technion; JCRB; PubMed=11416159; RCB; TKG
ST   Amelogenin: X
ST   CSF1PO: 9 (TKG)
ST   CSF1PO: 9,10 (Cosmic-CLP; Genomics_Center_BCF_Technion; JCRB; RCB)
ST   D10S1248: 12,13
ST   D12S391: 18,19
ST   D13S317: 8,13
ST   D16S539: 12
ST   D18S51: 15,20
ST   D19S433: 13,14
ST   D1S1656: 15,16
ST   D21S11: 29,30
ST   D22S1045: 17
ST   D2S1338: 24
ST   D2S441: 10
ST   D3S1358: 15,16
ST   D5S818: 8,11
ST   D7S820: 9,10
ST   D8S1179: 13
ST   FGA: 23
ST   Penta D: 12
ST   Penta E: 17,19
ST   TH01: 6,9
ST   TPOX: 11
ST   vWA: 16,19
DI   NCIt; C4648; Tongue squamous cell carcinoma
DI   ORDO; Orphanet_457252; Squamous cell carcinoma of the oral tongue
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   64Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 40
//
RX   PubMed=1570156;
RA   Sakai E., Tsuchida N.;
RT   "Most human squamous cell carcinomas in the oral cavity contain
RT   mutated p53 tumor-suppressor genes.";
RL   Oncogene 7:927-933(1992).
//
RX   PubMed=2228902; DOI=10.1007/BF02624609;
RA   Rikimaru K., Toda H., Tachikawa N., Kamata N., Enomoto S.;
RT   "Growth of the malignant and nonmalignant human squamous cells in a
RT   protein-free defined medium.";
RL   In Vitro Cell. Dev. Biol. 26:849-856(1990).
//
RX   PubMed=2585303; DOI=10.1111/j.1600-0714.1989.tb01570.x;
RA   Momose F., Araida T., Negishi A., Ichijo H., Shioda S., Sasaki S.;
RT   "Variant sublines with different metastatic potentials selected in
RT   nude mice from human oral squamous cell carcinomas.";
RL   J. Oral Pathol. Med. 18:391-395(1989).
//
RX   PubMed=7591301; DOI=10.1002/ijc.2910640504;
RA   Eura M., Ogi K., Chikamatsu K., Lee K.D., Nakano K., Masuyama K.,
RA   Itoh K., Ishikawa T.;
RT   "Expression of the MAGE gene family in human head-and-neck squamous-cell
RT   carcinomas.";
RL   Int. J. Cancer 64:304-308(1995).
//
RX   PubMed=9023415; DOI=10.1006/cimm.1996.1062;
RA   Seki N., Hoshino T., Kikuchi M., Hayashi A., Itoh K.;
RT   "HLA-A locus-restricted and tumor-specific CTLs in tumor-infiltrating
RT   lymphocytes of patients with non-small cell lung cancer.";
RL   Cell. Immunol. 175:101-110(1997).
//
RX   PubMed=9247707; DOI=10.1080/15216549700202901;
RA   Hatakeyama S., Gao Y.-H., Ohara-Nemoto Y., Kataoka H., Satoh M.;
RT   "Expression of bone morphogenetic proteins of human neoplastic
RT   epithelial cells.";
RL   Biochem. Mol. Biol. Int. 42:497-505(1997).
//
RX   PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D;
RA   Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T.,
RA   Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M.,
RA   Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.;
RT   "Screening the p53 status of human cell lines using a yeast functional
RT   assay.";
RL   Mol. Carcinog. 19:243-253(1997).
//
RX   PubMed=10069537; DOI=10.1111/j.1600-0714.1999.tb02006.x;
RA   Hoteiya T., Hayashi E., Satomura K., Kamata N., Nagayama M.;
RT   "Expression of E-cadherin in oral cancer cell lines and its
RT   relationship to invasiveness in SCID mice in vivo.";
RL   J. Oral Pathol. Med. 28:107-111(1999).
//
RX   PubMed=10741724;
RA   Eura M., Chikamatsu K., Katsura F., Obata A., Sobao Y., Takiguchi M.,
RA   Song Y.-S., Appella E., Whiteside T.L., DeLeo A.B.;
RT   "A wild-type sequence p53 peptide presented by HLA-A24 induces
RT   cytotoxic T lymphocytes that recognize squamous cell carcinomas of the
RT   head and neck.";
RL   Clin. Cancer Res. 6:979-986(2000).
//
RX   PubMed=11416159; DOI=10.1073/pnas.121616198;
RA   Masters J.R.W., Thomson J.A., Daly-Burns B., Reid Y.A., Dirks W.G.,
RA   Packer P., Toji L.H., Ohno T., Tanabe H., Arlett C.F., Kelland L.R.,
RA   Harrison M., Virmani A.K., Ward T.H., Ayres K.L., Debenham P.G.;
RT   "Short tandem repeat profiling provides an international reference
RT   standard for human cell lines.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:8012-8017(2001).
//
RX   PubMed=11755821; DOI=10.1016/S1368-8375(01)00022-7;
RA   Niinaka Y., Haga A., Negishi A., Yoshimasu H., Raz A., Amagasa T.;
RT   "Regulation of cell motility via high and low affinity autocrine
RT   motility factor (AMF) receptor in human oral squamous carcinoma
RT   cells.";
RL   Oral Oncol. 38:49-55(2002).
//
RX   PubMed=12738951; DOI=10.1067/moe.2003.36;
RA   Sugiyama M., Bhawal U.K., Dohmen T., Ono S., Miyauchi M., Ishikawa T.;
RT   "Detection of human papillomavirus-16 and HPV-18 DNA in normal,
RT   dysplastic, and malignant oral epithelium.";
RL   Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 95:594-600(2003).
//
RX   PubMed=17052259; DOI=10.1111/j.1349-7006.2006.00343.x;
RA   Kozaki K.-i., Imoto I., Pimkhaokham A., Hasegawa S., Tsuda H.,
RA   Omura K., Inazawa J.;
RT   "PIK3CA mutation is an oncogenic aberration at advanced stages of oral
RT   squamous cell carcinoma.";
RL   Cancer Sci. 97:1351-1358(2006).
//
RX   PubMed=17325662; DOI=10.1038/sj.onc.1210330;
RA   Nakaya K., Yamagata H.D., Arita N., Nakashiro K.-i., Nose M., Miki T.,
RA   Hamakawa H.;
RT   "Identification of homozygous deletions of tumor suppressor gene FAT
RT   in oral cancer using CGH-array.";
RL   Oncogene 26:5300-5308(2007).
//
RX   PubMed=17599052; DOI=10.1038/sj.onc.1210589;
RA   Suzuki E., Imoto I., Pimkhaokham A., Nakagawa T., Kamata N.,
RA   Kozaki K.-i., Amagasa T., Inazawa J.;
RT   "PRTFDC1, a possible tumor-suppressor gene, is frequently silenced in
RT   oral squamous-cell carcinomas by aberrant promoter hypermethylation.";
RL   Oncogene 26:7921-7932(2007).
//
RX   PubMed=18097548; DOI=10.3892/ijo.32.1.101;
RA   Murugan A.K., Hong N.T., Fukui Y., Munirajan A.K., Tsuchida N.;
RT   "Oncogenic mutations of the PIK3CA gene in head and neck squamous cell
RT   carcinomas.";
RL   Int. J. Oncol. 32:101-111(2008).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=30971826; DOI=10.1038/s41586-019-1103-9;
RA   Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M.,
RA   Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R.,
RA   Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P.,
RA   van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L.,
RA   Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.;
RT   "Prioritization of cancer therapeutic targets using CRISPR-Cas9
RT   screens.";
RL   Nature 568:511-516(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31978347; DOI=10.1016/j.cell.2019.12.023;
RA   Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III,
RA   Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K.,
RA   Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K.,
RA   Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A.,
RA   Sellers W.R., Gygi S.P.;
RT   "Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
RL   Cell 180:387-402.e16(2020).
//
RX   PubMed=32990596; DOI=10.7554/eLife.57761;
RA   Chai A.W.Y., Yee P.S., Price S., Yee S.M., Lee H.M., Tiong V.K.H.,
RA   Goncalves E., Behan F.M., Bateson J., Gilbert J.G.R., Tan A.-C.,
RA   McDermott U., Garnett M.J., Cheong S.-C.;
RT   "Genome-wide CRISPR screens of oral squamous cell carcinoma reveal
RT   fitness genes in the Hippo pathway.";
RL   eLife 9:e57761.1-e57761.34(2020).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//
RX   PubMed=37949965; DOI=10.1038/s41598-023-46926-y;
RA   Komune N., Sato K., Ono M., Imaizumi A., Masuda S., Itoyama S.,
RA   Manako T., Kuga R., Hongo T., Kogo R., Onishi H., Nakagawa T.;
RT   "Biological and genetic characterization of a newly established human
RT   external auditory canal carcinoma cell line, SCEACono2.";
RL   Sci. Rep. 13:19636-19636(2023).
//